China Drug Approvals | iPharmaCenter

AstraZeneca and Daiichi Sankyo’s drug, Enhertu approved in China for HER2-mutant mNSCLC | iPharmaCenter

AstraZeneca and Daiichi Sankyo’s drug, Enhertu (trastuzumab deruxtecan), have been granted conditional approval in China as a treatment...

China's NMPA Grants Approval for Padcev (Enfortumab Vedotin) for Advanced Urothelial Cancer | iPharmaCenter

China’s National Medical Products Administration (NMPA) has officially approved Padcev (enfortumab vedotin) for the treatment of adult...

Enhertu Receives Conditional Approval in China for Advanced HER2-Positive Gastric Cancer | iPharmaCenter

Enhertu, developed by AstraZeneca and Daiichi Sankyo, has gained conditional approval in China for use in patients with advanced or...

HUTCHMED's NDA for Tazemetostat in China Receives Priority Review for Relapsed/Refractory Follicular Lymphoma | iPharmaCenter

HUTCHMED (China) Limited has announced that the New Drug Application (NDA) for tazemetostat, aimed at treating adult patients with...

Leqembi Launched in China for Treating Alzheimer's Disease | 2024 | iPharmaCenter

Eisai and Biogen announced that the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody, Leqembi (ecanemab) (known in...

China Approves Tagrisso Combined with Chemotherapy as First-Line Treatment for Advanced EGFR-Mutated Lung Cancer | 2024 | iPharmaCenter

China’s National Medical Products Administration (NMPA) has granted approval for AstraZeneca’s Tagrisso (osimertinib), combined with...

China Drug Approvals | 2024 | iPharmaCenter

May 13, 2024 Eisai's Fycompa was approved for generalized tonic-clonic seizures Approved in China for the supplementary management of...

December 21, 2023 Takeda's Livtencity was approved in China for CMV infections Takeda declares the approval from China NMPA for...

Takeda announced that the National Medical Products Administration (NMPA) of China approved Exkivity (mobocertinib) for treating adults...

China Healthcare News | Drug News | iPharmaCenter

December 23, 2022 Eisai initiated data submission for BLA of lecanemab in China for Alzheimer's Eisai and Biogen announced that they have...